Amneal Pharmaceuticals price target lowered to $4 from $7 at Barclays

Barclays analyst Balaji Prasad lowered the firm’s price target on Amneal Pharmaceuticals to $4 from $7 and keeps an Overweight rating on the shares. The stock’s "steady slide" reflects challenges to levered names when EBITDA flatlines, the analyst tells investors in a research note. However, the firm believes Amneal is building a stronger margin business.